Urosaph Special Precautions

Mesna does not prevent hemorrhagic cystitis in all patients. Patients should be monitored accordingly. Sufficient urinary output should be maintained, as required for oxazaphosphorine treatment.
Sodium content: Mesna solution for injection contains approximately 59 mg of sodium per 400 mg mesna.
Lab test interferences: Mesna treatment may cause false positive reactions in nitroprusside sodium-based urine tests (including dipstick tests) for ketone bodies. The addition of glacial acetic acid can be used to differentiate between a false positive result (cherry-red color that fades) and a true positive result (red-violet color that intensifies).
Mesna treatment may cause false positive reactions in Tillman's reagent-based urine screening tests for ascorbic acid.
Effects on the ability to drive and use machines: Patients undergoing treatment with mesna may experience undesirable effects (including, e.g., syncope, light-headedness, lethargy/drowsiness, dizziness, and blurred vision) which could affect the ability to drive or use machines. The decision to drive or operate machinery should be made on an individual basis.